# Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

> **NCT00121953** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)**

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT00121953
- **Lead sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-07
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the recent meta-analysis about CV adverse effects.
- **Last updated:** 2012-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121953, "Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00121953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*